Investigator Initiated Trial of Syncrovax - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms
mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit
multiple immuno-pharmacologic effects.